Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936130 | 0.89 | PDE2A (0.56) | PDE2APDGFRBFGFR1KDRIKBKB | |
| SCHEMBL937313 | 0.82 | PDE2A (0.64) | PDE2APDGFRBFGFR1KDR | |
| SCHEMBL2680943 | 0.79 | MAOA (0.50) | PDE2APDGFRBFGFR1KDR | |
| SCHEMBL2680306 | 0.79 | PDE2A (0.70) | PDE2AIKBKBCHUK | |
| SCHEMBL936013 | 0.77 | CYP2D6 (0.46) | PDE2APDGFRBFGFR1KDRSYK | |
| SCHEMBL959055 | 0.77 | MAOA (0.43) | PDE2APDGFRBFGFR1KDR | |
| SCHEMBL17004334 | 0.75 | PDE2A (0.57) | PDE2AIKBKBCHUKSYK | |
| SCHEMBL2681127 | 0.73 | PDE2A (0.65) | PDE2APDGFRBFGFR1KDR | |
| SCHEMBL2681714 | 0.72 | PDE2A (0.76) | PDE2AIKBKBCHUK | |
| SCHEMBL965152 | 0.72 | PDE2A (0.65) | PDE2ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | claimed |
| EP-2456440-A1 | QUINOLINONE PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-05-30 | — | — | EP | claimed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | claimed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | claimed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | PDE12, PDE2A, PDE4A | PDE2A 2/4885MAPK14 2536/4885PDGFRB 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.